← Issue №20/
week of Nov 15, 2026/
the whole section, in full
Pancreas/Biliary, in full.
All 5 Pancreas/Biliary papers in this issue,
as full cards, ranked by clinical utility. The issue page carries the strongest few;
this is the section, whole.
Actionability = is there something to do. Prevalence = how much of a general GI practice it touches. Stakes = how consequential the decision is. Evidence strength = how far the study design and the result support the action. Novelty = how likely you are not already doing it.
Pancreas/Biliaryprospective cohort · n=641,915 · Nov 9, 2026 · J Hepatobil Pancreat Sci · IF 3.8
New evidenceepidemiologyhealth servicesbiliary stricture
Clinical takeawayHospital volume and transfusion were associated with 30-day mortality in administrative data, and the excess with transfusion may partly reflect operative complexity and severity; the authors call for further evaluation of selective centralization.
What it found30-day mortality declined from 0.5% to 0.3% over 8 years; highest-volume hospitals had lower mortality among transfused patients (3.3% vs. 4.4% in lowest-volume hospitals), despite higher transfusion rates (4.8% vs. 3.9%). Mortality increased across transfusion-volume categories (p-trend < 0.0001).
ContextNationwide Korean insurance cohort, 2012 to 2020; volume-mortality patterns among transfused patients were more prominent in tertiary referral hospitals.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Yoon J … Park B · Journal of Hepato-Biliary-Pancreatic Sciences · IF 3.8 · PubMed ↗Permalink
Pancreas/Biliaryretrospective · n=68 · Nov 13, 2026 · Pancreas · IF 1.9
Clinical takeawayA negative Kyoto HRS assessment does not exclude advanced neoplasia; the authors propose combining HRS with EUS-nCLE and cyst-fluid molecular testing (absent GNAS complemented nCLE, which was least sensitive in non-macropapillary lesions), pending prospective external validation.
What it foundAmong 68 resected BD-IPMNs, 38.2% had HGD/IC, concentrated in non-macropapillary lesions (53.1% vs 25.0%, P=0.017; micropapillary 71.4%). Kyoto HRS were 95.2% specific but 53.8% sensitive; 23.1% (12/52) of HRS-negative lesions harboured HGD/IC, mostly non-macropapillary, GNAS-negative and in the body or tail.
ContextRefines current practice: Kyoto HRS alone misses a significant subset of HGD/IC, particularly in non-macropapillary, GNAS-negative lesions. Adds evidence for multimodal preoperative assessment, with limitations in EUS-nCLE sensitivity for non-macropapillary lesions.
Measured against the standard of care· IAP Kyoto 2024 (Ohtsuka et al., Pancreatology 2024) / AGA Clinical Practice Update 2026 (Das, Serper, Vege, Clin Gastroenterol Hepatol 2026)ShowHide
Kyoto 2024 (IAP) is still the core algorithm for IPMN, and nothing in it has changed.…High-risk stigmata are: obstructive jaundice with a head cyst; an enhancing mural nodule >=5 mm or a solid component; MPD >=10 mm; or suspicious/positive cytology.…Under Kyoto, surveillance may stop for cysts <20 mm with no change and no WF after 5 years, and should stop if the patient is unfit for surgery or life expectancy is <10 years.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Kyoto 2024 (IAP) is still the core algorithm for IPMN, and nothing in it has changed. MD-, mixed- and BD-IPMN all go through one HRS/WF algorithm. MDCT, MRI/MRCP and EUS are treated as equivalent for diagnosis, with tumor markers and HbA1c added. Since 2024, EUS imaging and EUS-FNA cytology count toward HRS/WF when EUS is done. High-risk stigmata are: obstructive jaundice with a head cyst; an enhancing mural nodule >=5 mm or a solid component; MPD >=10 mm; or suspicious/positive cytology. Worrisome features are: pancreatitis; CA19-9 >37 U/mL; new-onset or worsening diabetes within 1 year; cyst >=30 mm; enhancing mural nodule <5 mm; thickened or enhancing cyst wall; MPD 5-9 mm; abrupt change in duct caliber with distal atrophy; lymphadenopathy; or growth >=2.5 mm/year. HRS should prompt consideration of resection, weighed against fitness and life expectancy; it does not mean automatic surgery. WF should prompt EUS and multidisciplinary review. EUS-FNA is used only when its result would change management. Surveillance of non-resected BD-IPMN depends on size: <20 mm at 6 months, then every 18 months; 20 to <30 mm every 6 months twice, then every 12 months; >=30 mm every 6 months. Under Kyoto, surveillance may stop for cysts <20 mm with no change and no WF after 5 years, and should stop if the patient is unfit for surgery or life expectancy is <10 years. Continued surveillance remains an option because the risk of a separate pancreatic cancer keeps accumulating. NEW in 2026: an AGA Clinical Practice Update (Das, Serper, Vege; expert opinion, not formally graded) adds stopping rules by age and comorbidity for any pancreatic cystic lesion. (1) At any age, patients with significant comorbidity (age-adjusted Charlson index >=3-5) and an incidental, especially low-risk, cyst should be counseled against routine surveillance. (2) Over 65, cysts <=15 mm stable for 5 years with no WF/HRS should be considered for stopping after shared decision-making. 'Stable' means growth under 3 mm/year and under 6 mm over 2 years. (3) Over 75, cysts <30 mm stable for 5 years with no WF/HRS call for a discussion of whether surveillance is worth continuing, and it may stop if the patient accepts the small residual risk. (4) If comorbidity develops that rules out surgery, stopping should be discussed, even when WF/HRS were found earlier, provided there is no evidence of HGD or cancer. (5) After resection with no HGD or cancer, the remnant follows the same rules, counting surveillance time before surgery, and stopping is discussed after 5 years of stability. (6) After resection with HGD, MRI/MRCP every 6 months for 2 years and then yearly while the patient can still have a completion pancreatectomy. If invasive cancer was found, the remnant follows oncology guidelines. In both cases, stopping is discussed with oncology after 5 years of remnant stability with no WF/HRS. The resect-all-MCNs rule and the familial/germline (CAPS) screening pathway come from other guidelines, not from either of these documents.
New evidencechronic pancreatitispancreatic cancerepidemiologypediatric
Clinical takeawayConsider lifelong follow-up and pancreatic cancer surveillance in PRSS1-associated hereditary pancreatitis, with strategies that account for risk rising with age and wide variation in age at diagnosis; diabetes was associated with higher cancer risk (HR 6.8).
What it foundPRSS1-associated hereditary pancreatitis carries a cumulative pancreatic ductal adenocarcinoma risk of 2.0% by age 50 and 5.9% by age 60, with a standardized incidence ratio of 32.2 (95% CI, 19.4-50.3).
ContextConfirms and quantifies the high pancreatic cancer risk in a nationwide French cohort (455 carriers with follow-up): penetrance 77.6%, median symptom onset 12.5 years, and cancer at a median age of 63.8 years.
Emergingsuggested applicable standard· American College of Gastroenterology, 'ACG Clinical Guideline: Chronic Pancreatitis' (Gardner TB et al., Am J Gastroenterol 2020;115(3):322-339). DOI 10.14309/ajg.0000000000000535, PMID 32022720.ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Confirm chronic pancreatitis on CROSS-SECTIONAL IMAGING, CT for late calcific disease, MRI/MRCP (with secretin where available) for earlier ductal and parenchymal change, EUS an acceptable alternative; per ACG 2020, "Diagnosis is made usually on cross-sectional imaging, with modalities such as endoscopic ultrasonography and pancreatic function tests playing a secondary role". Fecal elastase does NOT confirm chronic pancreatitis: it is a test of exocrine FUNCTION and is the appropriate initial test for the exocrine pancreatic insufficiency (EPI) that chronic pancreatitis causes, a consequence of the disease, not the diagnosis of it. A normal fecal elastase does not exclude chronic pancreatitis and a low one does not establish it. Per AGA 2023, fecal elastase must be run on a semi-solid or solid stool specimen; below 100 mcg/g is good evidence of EPI and 100-200 mcg/g is indeterminate (below 200 mcg/g is the cutoff commonly used to screen). Then manage with smoking and alcohol cessation, PERT for exocrine insufficiency titrated to symptoms, fat-soluble vitamin and bone surveillance, and individualized type 3c diabetes control, considering insulin early in patients with marked hyperglycemia or symptoms of insulin deficiency. Treat pain with a stepwise ladder from scheduled acetaminophen and neuromodulators to EUS-guided celiac plexus block and endoscopic/surgical intervention, referring early for surgery per ESCAPE 2020 in candidates with main pancreatic duct obstruction. Screen for PDAC per lifetime risk and pursue etiologic workup via TIGAR-O v2, including genetic testing and autoimmune pancreatitis evaluation.
Cléry G … Rebours V · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Pancreas/Biliaryprospective cohort · n=387 · Nov 14, 2026 · J Gastroenterology · IF 5.7
Clinical takeawayIn this retrospective registry, resection and, for non-resectable disease, chemotherapy including FOLFIRINOX were associated with longer survival; treatments were not compared prospectively.
What it foundFive-year survival was 55.3% after resection vs 4.5% without (p < 0.001). In non-resected patients, absence of chemotherapy was associated with worse prognosis and FOLFIRINOX with longer survival; AFP-positive immunostaining and Ki-67 ≥30% were independent adverse factors.
ContextNationwide study of a rare malignancy (387 patients, 85 centres); older age, non-resection and advanced stage were independently associated with shorter survival, and total pancreatectomy and recurrence with lower survival after resection.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Kanno A … Japan Pancreas Society Clinical Research Promotion Committee Group (Corporate Authorship) · Journal of Gastroenterology · IF 5.7 · PubMed ↗Permalink
Pancreas/Biliaryretrospective · n=17,374 · Nov 11, 2026 · Pancreatology · IF 3.0
Clinical takeawayConsider neuroendocrine and solid pseudopapillary tumors in the differential diagnosis of pancreatic neoplasms in patients under 50, as these histologies are more common in this age group. Ensure appropriate diagnostic imaging and histologic confirmation.
What it foundEarly-onset pancreatic neoplasms (<50 years) had a median survival of 13.1 months vs 5.5 months in later-onset cases, with higher rates of neuroendocrine (22.4% vs 6.8%) and solid pseudopapillary histology (5.9% vs 0.3%).
ContextRefines understanding of pancreatic neoplasms in younger patients, highlighting distinct histologic patterns and better survival outcomes compared to older patients. The findings are based on a hospital-based registry in São Paulo, Brazil.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Szor DJ … Ribeiro U · Pancreatology : Official Journal of the International Association of Pancreatology (IAP) .. [et Al.] · IF 3.0 · PubMed ↗Permalink